COMMUNIQUÉS West-GlobeNewswire

Marinus Pharmaceuticals Phase 2 Clinical Trial Data Show Long-term Effectiveness of Ganaxolone in Reducing Seizure Frequency in CDKL5 Deficiency Disorder Patients
04/12/2018
Predictive biomarker also identified in PCDH19-related pediatric epilepsy RADNOR, Pa., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical [...]
TG Therapeutics, Inc. Announces Follow-Up Data from the Triple Combination of Ublituximab, Umbralisib, and Bendamustine in Patients with DLBCL and FL at 60th American Society of Hematology Annual Meeting and Exposition
04/12/2018
NEW YORK, Dec. 04, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced updated clinical data from its Phase I/Ib trial of ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 [...]
Dermira Enters into Credit Facility with Athyrium Capital Management
04/12/2018
Facility provides additional financial flexibility in connection with ongoing QBREXZA launch and lebrikizumab program MENLO PARK, Calif., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a [...]
Lenzilumab Data Presented in Oral Presentation at the American Society of Hematology (ASH)
04/12/2018
Lenzilumab (an anti-GM-CSF antibody) in combination with CAR-T cell therapy prevents cytokine release syndrome and neuroinflammation while improving durable control of leukemic disease Exponential increase in T cell [...]
ExCellThera announces results of clinical trial using ECT-001 for blood cancers
04/12/2018
MONTREAL, Dec. 04, 2018 (GLOBE NEWSWIRE) -- ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, today announced results from [...]
Tetra Bio-Pharma Convenes First National Medical Advisory Board
04/12/2018
Key Opinion Leaders Weigh in on Scientific Research in Cannabinoids ORLEANS, Ontario, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc (“ Tetra ” or “ TBP ”), (TSX VENTURE: TBP) (OTCQB: TBPMF), – announced that it [...]
ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients
04/12/2018
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the [...]
Emerald Joint Venture Receives Licenses from Health Canada to Sell Proprietary Products Supporting the Endocannabinoid System
04/12/2018
Endo Brain recently awarded 2018 SupplySide Editor’s Choice Award for Brain Health Planned mid-2019 product launch will open natural health product, grocery, and pharmacy store channels to Emerald non-cannabis product [...]
Pluristem Therapeutics Enters into Cell Thawing Device License Agreement with Chart Industries, Inc.
04/12/2018
HAIFA, Israel, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that [...]
Preliminary Results from Randomized Phase 2 Trial Demonstrate Trilaciclib Improved Progression-Free Survival in Combination with Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer
04/12/2018
Patients on trilaciclib received more chemotherapy cycles than those in the control arm Trilaciclib showed multi-lineage myelopreservation benefits when adjusting for longer duration of treatment Safety profile [...]
RavenQuest Begins Cannabis Sales
04/12/2018
VANCOUVER, British Columbia, Dec. 04, 2018 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT ) is pleased to announce that it is concluding its first [...]
INSYS Therapeutics Presents New Clinical Data from Long-Term Safety Study of CBD Oral Solution in Refractory Pediatric Epilepsy
04/12/2018
PHOENIX, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Pharmaceutical-grade cannabidiol (CBD) oral solution made by INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of [...]
Transactions in relation to share buyback program
04/12/2018
Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
Lundbeck announces retirement of Anders Gersel Pedersen, EVP and Head of Research and Development
04/12/2018
Valby, Denmark, 4 December 2018 - H. Lundbeck A/S (Lundbeck) today announced that Anders Gersel Pedersen, Executive Vice President and Head of Research and Development (R&D), will retire after 19 years with the [...]
Rule 2.9 Announcement
04/12/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 4 December 2018 [...]
Viracta and Salubris Announce Equity Financing and Partnership to Bring Novel Treatment for Viral-Associated Cancers to China
04/12/2018
SAN DIEGO and SHENZHEN, China, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Shenzhen Salubris Pharmaceuticals Co. Ltd. (Salubris, SZSE: 002294) and Viracta Therapeutics, Inc. announced the initial closing of a financing, with [...]
Updated Interim Results from Ongoing Phase 2a Study of Portola Pharmaceuticals’ Oral Syk/JAK Inhibitor Cerdulatinib Continues to Demonstrate Clinical Responses in Heavily Pre-Treated T-Cell Malignancies
04/12/2018
– Early Signs of Durable Response Across Patients with Relapsed/Refractory PTCL – – 50 Percent Complete Response Rate Observed in Patients with AITL – – Rapid and Significant Reduction in Itching Among Patients with [...]
Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting
04/12/2018
P-BCMA-101 showed a 100% ORR with patients achieving rapid and deep responses with no CRS or neurotoxicity observed at the planned Phase 2 dose SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a [...]
Atara Biotherapeutics Announces Next-Generation CAR T Discoveries and Positive T-Cell Immunotherapy Results in Patients with EBV+ PTLD Involving the CNS at 60th American Society of Hematology (ASH) Annual Meeting
04/12/2018
Moffitt Cancer Center collaborators described next-generation chimeric antigen receptor T-cell (CAR T) technology that increases T cell persistence and decreases exhaustion Memorial Sloan Kettering collaborators [...]

Pages